Simplex Trading
AUTL

Simplex Trading’s Autolus Therapeutics AUTL Stock Holding History

Simplex Trading’s Portfolio AUTL Stock Details AUTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-3,800
Closed -$6K – 8510
2025
Q3 		$6K Hold
3,800
– – ﹤0.01% 8154
2025
Q2 		$8K Sell
3,800
-1,300
-25% -$2.15K ﹤0.01% 7440
2025
Q1 		$7K Sell
5,100
-20,900
-80% -$42.4K ﹤0.01% 7286
2024
Q4 		$61K Buy
26,000
+17,400
+202% +$58.8K ﹤0.01% 5661
2024
Q3 		$31K Buy
8,600
+8,300
+2,767% +$33.1K ﹤0.01% 6317
2024
Q2 		$1K Sell
300
-8,700
-97% -$37.5K ﹤0.01% 8411
2024
Q1 		$57K Buy
+9,000
New +$56.1K ﹤0.01% 6133
2022
Q4 		– Sell
-500
Closed -$1K – 9174
2022
Q3 		$1K Buy
+500
New +$1.48K ﹤0.01% 9481
2022
Q2 		– Sell
-2,500
Closed -$10K – 9910
2022
Q1 		$10K Buy
2,500
+2,300
+1,150% +$9.67K ﹤0.01% 8845
2021
Q4 		$1K Buy
+200
New +$1.2K ﹤0.01% 10136

Other funds holding AUTL

MCO
MAK Capital One New York $714M AUM 68.07% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
SP
Syncona Portfolio St Peter Port, Guernsey $26.6M AUM 10.36% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $635M AUM 28.07% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Simplex Trading's AUTL Position: Q2 2026 in Review

Simplex Trading sold out of Autolus Therapeutics (AUTL) in Q2 2026, closing a stake of 23,641 shares — an estimated $37.1K sold.

Simplex Trading first reported a position in AUTL in Q3 2023 and held it in 10 quarters. The position peaked at $115K in Q4 2025. 83 funds tracked by Wall St. Rank hold AUTL as of Q2 2026.

  • Simplex Trading reported no remaining Autolus Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Simplex Trading sold 23,641 Autolus Therapeutics shares in Q2 2026, an estimated $37.1K.
  • Simplex Trading first reported a position in Autolus Therapeutics in Q3 2023 and held it in 10 quarters.
  • Simplex Trading's Autolus Therapeutics position peaked at $115K in Q4 2025.
  • 83 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q2 2026.

Based on Simplex Trading's 13F filing for Q2 2026, filed 12 Aug 2026.